SHIJIAZHUANG CITY, China – (BUSINESS WIRE) – Recently, the National Health Commission of China and the State Administration of Traditional Chinese Medicine jointly published the Diagnostic and treatment protocol for COVID-19 (test version 8), recommending that Lianhua Qingwen Capsule, a traditional Chinese medicine, be used during the medical observation period of patients with COVID-19.
The selection of Lianhua Qingwen for the protocol demonstrates the recognition of the Chinese authorities for their excellent performance in controlling COVID-19 in China. It is known that during the pandemic, Lianhua Qingwen was widely used in designated hospitals and medical institutions in China, and has become the most recommended Chinese medicine in COVID-19 treatment programs in the country’s provinces and municipalities.
This is not the first time that Lianhua Qingwen has appeared publicly as an official recommended medicine in China. In 2003, Lianhua Qingwen was developed by Yiling Pharmaceutical in response to the “SARS” pandemic. Research into its effect on SARS at the Chinese Academy of Military Medical Sciences has revealed that it can significantly inhibit SARS virus replication. In 2015, when another coronavirus caused the Middle East respiratory syndrome, the National Health Commission also explicitly recommended Lianhua Qingwen Capsule as the preventive medical treatment drug in its plan.
The Lianhua Qingwen capsule was recently approved by the Philippine Food and Drug Administration and entered the Philippine market on November 23. In view of its crucial role in important public health events, Filipino experts hope that Lianhua Qingwen will be useful in combating COVID-19 in the Philippines after entering the market and providing assistance to the Filipino government and people.